Reliability and Extension of Quantitative Prediction of CYP3A4-Mediated Drug Interactions Based on Clinical Data

An approach was proposed in 2007 for quantitative predictions of cytochrome P450 (CYP)3A4-mediated drug-drug interactions. It is based on two characteristic parameters: the contribution ratio (CR; i.e., the fraction of victim drug clearance by CYP) and the inhibition ratio (IR) of the inhibitor. Knowledge of these parameters allows forecasting of the ratio between the area under the plasma concentration-time curve (AUC) of the victim drug when given with the inhibitor and the AUC of the victim drug when it is given alone. So far, these parameters were established for 21 substrates and 17 inhibitors. The goals of our study were to test the assumption of substrate independence of the potency of inhibitors in vivo and to estimate the CR and IR for an extended list of substrates and inhibitors of CYP3A4. The assumption of independence of IRs from the substrate was evaluated on a set of eight victim drugs and eight inhibitors. Forty-four AUC ratios were available. This assumption was rejected in four cases, but it did not result in more than a twofold error in AUC ratio predictions. The extended list of substrates and inhibitors was defined by a thorough literature search. Fifty-nine AUC ratios were available for the global analysis. Final estimates of CRs and IRs were obtained for 37 substrates and 25 inhibitors, respectively. The mean prediction error of the ratios was 0.02, while the mean absolute prediction error was 0.58. Predictive distributions for 917 possible interactions were obtained, giving detailed information on some drugs or inhibitors that have been poorly studied so far.

[1]  F. Gueyffier,et al.  Impact of Genetic Polymorphism on Drug-Drug Interactions Mediated by Cytochromes: A General Approach , 2013, The AAPS Journal.

[2]  F. Gueyffier,et al.  Quantitative Prediction of the Impact of Drug Interactions and Genetic Polymorphisms on Cytochrome P450 2C9 Substrate Exposure , 2013, Clinical Pharmacokinetics.

[3]  S. Goutelle,et al.  In Vivo Quantitative Prediction of the Effect of Gene Polymorphisms and Drug Interactions on Drug Exposure for CYP2C19 Substrates , 2013, The AAPS Journal.

[4]  E. Greanya,et al.  A review of drug interactions with boceprevir and telaprevir: implications for HIV and transplant patients. , 2012, Annals of hepatology.

[5]  Gopal Krishna,et al.  Effect of posaconazole on the pharmacokinetics of simvastatin and midazolam in healthy volunteers , 2012, Expert opinion on drug metabolism & toxicology.

[6]  A. Collier,et al.  Complex Drug Interactions of HIV Protease Inhibitors 2: In Vivo Induction and In Vitro to In Vivo Correlation of Induction of Cytochrome P450 1A2, 2B6, and 2C9 by Ritonavir or Nelfinavir , 2011, Drug Metabolism and Disposition.

[7]  S. Goutelle,et al.  Quantitative Prediction of Cytochrome P450 (CYP) 2D6-Mediated Drug Interactions , 2011, Clinical pharmacokinetics.

[8]  R. Terkeltaub,et al.  Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P-glycoprotein inhibitors. , 2011, Arthritis and rheumatism.

[9]  A. Collier,et al.  Complex Drug Interactions of HIV Protease Inhibitors 1: Inactivation, Induction, and Inhibition of Cytochrome P450 3A by Ritonavir or Nelfinavir , 2011, Drug Metabolism and Disposition.

[10]  Amin Rostami-Hodjegan,et al.  Assessment of algorithms for predicting drug-drug interactions via inhibition mechanisms: comparison of dynamic and static models. , 2009, British journal of clinical pharmacology.

[11]  L. Wienkers,et al.  Selection of Alternative CYP3A4 Probe Substrates for Clinical Drug Interaction Studies Using In Vitro Data and In Vivo Simulation , 2010, Drug Metabolism and Disposition.

[12]  Y. Adler,et al.  Colchicine for pericarditis: hype or hope? , 2009, European heart journal.

[13]  C. Robert,et al.  Bayesian Modeling Using WinBUGS , 2009 .

[14]  Shufeng Zhou.  Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. , 2008, Current drug metabolism.

[15]  Akihiro Hisaka,et al.  General Framework for the Prediction of Oral Drug Interactions Caused by CYP3A4 Induction from In Vivo Information , 2008, Clinical pharmacokinetics.

[16]  Shufeng Zhou,et al.  Clinically Important Drug Interactions Potentially Involving Mechanism-based Inhibition of Cytochrome P450 3A4 and the Role of Therapeutic Drug Monitoring , 2007, Therapeutic drug monitoring.

[17]  H. Hachad,et al.  Quantitative correlations among CYP3A sensitive substrates and inhibitors: literature analysis. , 2007, Current drug metabolism.

[18]  Amarnath Sharma,et al.  Steady-State Pharmacokinetic and Safety Profiles of Voriconazole and Ritonavir in Healthy Male Subjects , 2007, Antimicrobial Agents and Chemotherapy.

[19]  Akihiro Hisaka,et al.  General Framework for the Quantitative Prediction of CYP3A4-Mediated Oral Drug Interactions Based on the AUC Increase by Coadministration of Standard Drugs , 2007, Clinical pharmacokinetics.

[20]  J. Houston,et al.  The Utility of in Vitro Cytochrome P450 Inhibition Data in the Prediction of Drug-Drug Interactions , 2006, Journal of Pharmacology and Experimental Therapeutics.

[21]  A. Galetin,et al.  Multisite kinetic analysis of interactions between prototypical CYP3A4 subgroup substrates: midazolam, testosterone, and nifedipine. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[22]  H. Schmidli,et al.  Pharmacokinetics and electrocardiographic pharmacodynamics of artemether-lumefantrine (Riamet) with concomitant administration of ketoconazole in healthy subjects. , 2002, British journal of clinical pharmacology.

[23]  Stephen J. Ganocy,et al.  Bayesian Statistical Modelling , 2002, Technometrics.

[24]  G. Muirhead,et al.  The effects of steady-state erythromycin and azithromycin on the pharmacokinetics of sildenafil in healthy volunteers. , 2002, British journal of clinical pharmacology.

[25]  J. Houston,et al.  Multisite kinetic models for CYP3A4: simultaneous activation and inhibition of diazepam and testosterone metabolism. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[26]  A. Puech,et al.  Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects. , 2001, British journal of clinical pharmacology.

[27]  J. R. Scotti,et al.  Available From , 1973 .

[28]  P. Neuvonen,et al.  Diltiazem and mibefradil increase the plasma concentrations and greatly enhance the adrenal‐suppressant effect of oral methylprednisolone , 2000, Clinical pharmacology and therapeutics.

[29]  J. Spence,et al.  Pharmacokinetic-Pharmacodynamic Consequences and Clinical Relevance of Cytochrome P450 3A4 Inhibition , 2000, Clinical pharmacokinetics.

[30]  K. Brøsen,et al.  Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine. , 1999, British journal of clinical pharmacology.

[31]  J B Houston,et al.  CYP3A4 drug interactions: correlation of 10 in vitro probe substrates. , 1999, British journal of clinical pharmacology.

[32]  D. Bailey,et al.  Grapefruit juice-drug interactions. , 1998, British journal of clinical pharmacology.

[33]  R. Davies,et al.  Pharmacokinetic and pharmacodynamic interactions between diltiazem and quinidine , 1996, Clinical pharmacology and therapeutics.

[34]  M. Rubenfire,et al.  The effect of coadministration of verapamil on the pharmacokinetics and metabolism of quinidine , 1987, Clinical pharmacology and therapeutics.

[35]  W. Jusko,et al.  Effects of ketoconazole on methylprednisolone pharmacokinetics and cortisol secretion , 1986, Clinical pharmacology and therapeutics.